Immune Regulation News Volume 6.46 | Dec 5 2014

    0
    84

    Immune Regulation News 6.46 December 5, 2014

    Immune Regulation News

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  IRN on Twitter

     
    TOP STORY
    Deubiquitinase DUBA Is a Post-Translational Brake on Interleukin-17 Production in T Cells
    Researchers show that the deubiquitylating enzyme DUBA is a negative regulator of interleukin-17A production in T cells. Mice with DUBA-deficient T cells developed exacerbated inflammation in the small intestine after challenge with anti-CD3 antibodies. [Nature] Abstract
    Free Poster: Quick Reference for Mouse Immune Cell Frequencies and Percentages

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    Regulatory iNKT Cells Lack Expression of the Transcription Factor PLZF and Control the Homeostasis of Treg Cells and Macrophages in Adipose Tissue
    Researchers found that adipose invariant natural killer T (iNKT) cells were a tissue-resident population that induced an anti-inflammatory phenotype in macrophages and, through the production of interleukin 2, controlled the number, proliferation and suppressor function of regulatory T (Treg) cells in adipose tissue. [Nat Immunol] Abstract

    A p85α-Osteopontin Axis Couples the Receptor ICOS to Sustained Bcl-6 Expression by Follicular Helper and Regulatory T Cells
    Investigators report that activation of ICOS in CD4+ T cells promoted interaction of the p85α regulatory subunit of the signaling kinase PI3K and intracellular osteopontin (OPN-i), followed by translocation of OPN-i to the nucleus, its interaction with Bcl-6 and protection of Bcl-6 from ubiquitin-dependent proteasome degradation. [Nat Immunol] Abstract

    The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
    TIGIT is highly expressed on human and murine tumor-infiltrating T cells, and, in models of both cancer and chronic viral infection, antibody coblockade of TIGIT and PD-L1 synergistically and specifically enhanced CD8+ T cell effector function, resulting in significant tumor and viral clearance, respectively. [Cancer Cell]
    Abstract | Graphical Abstract

    Multiple Functional Therapeutic Effects of the Estrogen Receptor β Agonist Indazole-Cl in a Mouse Model of Multiple Sclerosis
    Therapeutic indazole chloride improved clinical disease and rotorod performance and also decreased peripheral Th1 cytokines and reactive astrocytes, activated microglia, and T cells in brains of experimental autoimmune encephalomyelitis mice. [Proc Natl Acad Sci USA] Abstract | Full Article | Press Release

    Activation of Toll-Like Receptor-2 by Endogenous Matrix Metalloproteinase-2 Modulates Dendritic-Cell-Mediated Inflammatory Responses
    Investigators show that matrix metalloproteinase-2 (MMP-2) directly stimulates dendritic cells to both upregulate OX40L on the cell surface and secrete inflammatory cytokines. MMP-2 polarizes T cells toward type 2 responses in vivo, in a Toll-like receptor-2-dependent manner. [Cell Rep]
    Full Article | Graphical Abstract | Press Release

    Regulatory T Cells Occupy an Isolated Niche in the Intestine that Is Antigen Independent
    Regulatory T cells (Tregs) require antigen-specific signals via T cell receptor-major histocompatibility complex class II (TCR-MHCII) interactions for their development. Scientists examined lamina propria Treg homeostasis in a transgenic mouse model that lacks peripheral TCR-MHCII interactions and generation of extrathymic Tregs. [Cell Rep] Full Article | Graphical Abstract

    Splenic B Cells from Hymenolepis diminuta-Infected Mice Ameliorate Colitis Independent of T Cells and via Cooperation with Macrophages
    In response to H. diminuta, a putatively unique splenic CD19+ B cell with a functional immunoregulatory program is generated that promotes the suppression of colitis dominated by TH1, TH2, or TH1-plus-TH2 events, and may do so via the synthesis of TGF-β and the generation of, or cooperation with, a regulatory macrophage. [J Immunol] Abstract

    Natural Killer T Cells Play a Necessary Role in Modulating of Immune-Mediated Liver Injury by Gut Microbiota
    Oral administration of pathogenic bacteria or gentamycin to mice before ConA injection, liver injury and lymphocyte distribution in liver and intestine were assessed. Activation-induced natural killer T cells were downregulated in the liver of pathogenic bacteria-treated ConA groups. [Sci Rep] Full Article

    DNA Vaccination Strategy Targets Epidermal Dendritic Cells, Initiating Their Migration and Induction of a Host Immune Response
    Scientists demonstrate that intradermally electroporation-enhanced pDNA vaccination results in the rapid induction of a host humoral immune response. Furthermore, they delineate the relationship between the migration of directly transfected epidermal dendritic cells and the generation of the host immune response. [Mol Ther Methods Clin Dev] Full Article

    Subscribe to our sister publications:
    Human Immunology News and Immunology of Infectious Disease News
    !

    Air-Liquid Interface Culture for Respiratory Research: Watch Q&A Video

     
    REVIEWS
    Crosstalk at the Mucosal Border: Importance of the Gut Microenvironment in IBS
    The authors highlight the crosstalk between the gut microbiota, the enteroendocrine system, the immune system and the role of intestinal permeability in patients with IBS. [Nat Rev Gastroenterol Hepatol] Abstract

    Visit our reviews page to see a complete list of reviews in the immune regulation research field.

     
    SCIENCE NEWS
    Aduro Biotech Announces Preclinical Data
    Aduro Biotech, Inc. announced data demonstrating potent anti-tumor activity in preclinical models treated with ADU-S100, a proprietary molecule based on the company’s cyclic dinucleotide platform technology. [Press release from Aduro Biotech, Inc. (Business Wire) discussing research presented at the American Association for Cancer Research (AACR) 2014 Immunology and Immunotherapy Meeting, Orlando] Press Release

    ZIOPHARM and Intrexon Present Clinical and Preclinical Data
    ZIOPHARM Oncology, Inc. and Intrexon Corporation announced the presentation of clinical and preclinical studies from their immuno-oncology programs. [Press release from ZIOPHARM Oncology, Inc. discussing research presented at the American Association for Cancer Research (AACR) 2014 Immunology and Immunotherapy Meeting, Orlando] Press Release

    Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen with Intratumoral IMO-2055 Demonstrated Potent and Systemic Anti-Tumor Activity in Preclinical Models
    Idera Pharmaceuticals, Inc. announced new preclinical data that showed cancer immunotherapy with intratumoral injections of IMO-2055 and ipilimumab demonstrated potent and systemic anti-tumor activity in multiple preclinical cancer models. [Press release from Idera Pharmaceuticals, Inc. discussing research presented at the American Association for Cancer Research (AACR) 2014 Immunology and Immunotherapy Meeting, Orlando] Press Release

    Genentech to Present Clinical Data from Six Different Medicines
    Genentech announced that new data on four investigational medicines and investigational uses for two approved hematology medicines will be presented. [Press release from Genentech, Inc. discussing research to be presented at the 56th American Society of Hematology (ASH) Annual Meeting, San Francisco] Press Release

    From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.

     
    INDUSTRY NEWS
    FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Amgen announced that the U.S. Food and Drug Administration (FDA) has granted approval of BLINCYTO™ for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. [Amgen Inc.] Press Release

    TxCell Announces Start of Phase IIb Clinical Trial with Ovasave® for Refractory Crohn’s Disease
    TxCell SA announced that it has enrolled the first patient in its Phase IIb clinical trial of its lead product Ovasave® in refractory Crohn’s disease. [TxCell SA] Press Release

    MRIGlobal Wins Contract to Produce HPV Vaccine
    MRIGlobal announced that it has been awarded a $3 million contract amendment from the National Cancer Institute’s PREVENT Cancer Program to provide a vaccine for the Human Papillomavirus or HPV. MRIGlobal will lead a team that will produce the vaccine to be used in a Phase I clinical trial. [MRIGlobal] Press Release

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW The 54th Midwinter Conference of Immunologists
    January 24-27, 2015
    Pacific Grove, United States

    NEW Keystone Symposium – Tumor Immunology: Multidisciplinary Science Driving Combination Therapy
    February 8-13, 2015
    Banff, Canada

    Visit our events page to see a complete list of events in the immune regulation community.

     
    JOB OPPORTUNITIES
    NEW Postdoctoral Research Associate – Immunology (University of Edinburgh)

    NEW Postdoctoral Position РImmunology (Centre L̩on B̩rard)

    Postdoctoral Position – Mucosal Immunology (Karolinska Institute)

    Research Associate – B Cell Biology (King’s College London)

    Researcher – Antitumor Immune Cell Response (ACAVI)

    Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

    Postdoctoral Fellow – Genetic and Epigenetic Regulatory Networks in Protective Immune Responses (Washington University School of Medicine)

    PhD Studentship – Cancer Immunology (Cardiff University)

    Scientist – Recombinant Molecules and Antibodies (STEMCELL Technologies Inc.)

    Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

    Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Immune Regulation News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Immune Regulation News: Archives | Events | Contact Us